For research use only. Not for therapeutic Use.
Ciluprevir（Cat No.:I006005）is a potent NS3/4A protease inhibitor developed for the treatment of hepatitis C virus (HCV) infections. By blocking the HCV protease, it disrupts viral polyprotein processing, effectively halting replication. Ciluprevir exhibits strong antiviral activity against multiple HCV genotypes, making it a valuable tool in antiviral research. Although it was discontinued due to safety concerns, it has provided significant insights into the design of next-generation protease inhibitors. Ciluprevir remains important in understanding viral replication mechanisms and optimizing therapies for managing chronic HCV infections.
| Catalog Number | I006005 |
| CAS Number | 300832-84-2 |
| Synonyms | BILN 2061; BILN-2061; BILN2061; BILN-2061ZW; BILN2061ZW; BILN 2061ZW; Ciluprevir;(2R,6S,13aS,14aR,16aS,Z)-6-(((cyclopentyloxy)carbonyl)amino)-2-((2-(2-(isopropylamino)thiazol-4-yl)-7-methoxyquinolin-4-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15, |
| Molecular Formula | C40H50N6O8S |
| Purity | ≥95% |
| Target | HCV Protease |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (1S,4R,6S,7Z,14S,18R)-14-(cyclopentyloxycarbonylamino)-18-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid |
| InChI | InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1 |
| InChIKey | PJZPDFUUXKKDNB-KNINVFKUSA-N |
| SMILES | CC(C)NC1=NC(=CS1)C2=NC3=C(C=CC(=C3)OC)C(=C2)O[C@@H]4C[C@H]5C(=O)N[C@@]6(C[C@H]6/C=C\CCCCC[C@@H](C(=O)N5C4)NC(=O)OC7CCCC7)C(=O)O |
